Abstract
Lithium (Li+) is a first option treatment for adult acute episodes of Bipolar Disorder (BD) and for the prophylaxis of new depressed or manic episodes. It is also the preferred choice as maintenance treatment. Numerous studies have shown morphological abnormalities in the brains of BD patients, suggesting that this highly heritable disorder may exhibit progressive and deleterious changes in brain structure. Since treatment with Li+ ameliorates these abnormalities, it has been postulated that Li+ is a neuroprotective agent in the same way atypical antipsychotics are neuroprotective in patients diagnosed with schizophrenia spectrum disorders. Li+’s neuroprotective properties are related to its modulation of nerve growth factors, inflammation, mitochondrial function, oxidative stress, and programmed cell death mechanisms such as autophagy and apoptosis. Notwithstanding, it is not known whether Li+—induced neuroprotection is related to the inhibition of its putative molecular targets in a BD episode: the enzymes inositol-monophosphatase, (IMPase), glycogen-synthase-kinase 3β (GSK3), and Protein kinase C (PKC). Furthermore, it is uncertain whether these neuroprotective mechanisms are correlated with Li+’s clinical efficacy in maintaining mood stability. It is expected that in a nearby future, precision medicine approaches will improve diagnosis and expand treatment options. This will certainly contribute to ameliorating the medical and economic burden created by this devastating mood disorder.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- AD:
-
Alzheimer’s disease
- BD:
-
Bipolar disorder
- BD I:
-
Bipolar disorder I
- BD II:
-
Bipolar disorder II
- BDNF:
-
Brain-derived neurotrophic factor
- DAG:
-
Diacylglycerol
- HD:
-
Huntington’s disease
- IMPase:
-
Inositol monophosphatase
- IP:
-
Inositol monophosphate
- IP3 :
-
Inositol-1-4-5 triphosphate
- Li+ :
-
Lithium
- MRI:
-
Magnetic resonance imaging
- PD:
-
Parkinson’s disease
- PI:
-
Phosphatidylinositol
- PIP2 :
-
Phosphatidylinositol-4,5-biphosphate
- PKC:
-
Protein kinase C
- SCZ:
-
Schizophrenia/SCZ spectrum disorders
- GSK3:
-
Glycogen-synthase-kinase 3β
References
Abe C, Ekman CJ, Sellgren C, Petrovic P, Ingvar M, Landen M (2016) Cortical thickness, volume and surface area in patients with bipolar disorder types I and II. J Psychiatry Neurosci 41(4):240–250. https://doi.org/10.1503/jpn.150093
Abe C, Liberg B, Song J, Bergen SE, Petrovic P, Ekman CJ, Sellgren CM, Ingvar M, Landen M (2020) Longitudinal cortical thickness changes in bipolar disorder and the relationship to genetic risk, mania, and lithium use. Biol Psychiatry 87(3):271–281. https://doi.org/10.1016/j.biopsych.2019.08.015
Alda M (2015) Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics. Mol Psychiatry 20(6):661–670. https://doi.org/10.1038/mp.2015.4
Alessenko A, Khan WA, Wetsel WC, Hannun YA (1992) Selective changes in protein kinase C isoenzymes in rat liver nuclei during liver regeneration. Biochem Biophys Res Commun 182(3):1333–1339. https://doi.org/10.1016/0006-291x(92)91879-u
Amiri S, Jafari-Sabet M, Keyhanfar F, Falak R, Shabani M, Rezayof A (2020) Hippocampal and prefrontal cortical NMDA receptors mediate the interactive effects of olanzapine and lithium in memory retention in rats: the involvement of CAMKII-CREB signaling pathways. Psychopharmacology 237(5):1383–1396. https://doi.org/10.1007/s00213-020-05465-4
Amrollahi Z, Rezaei F, Salehi B, Modabbernia AH, Maroufi A, Esfandiari GR, Naderi M, Ghebleh F, Ahmadi-Abhari SA, Sadeghi M, Tabrizi M, Akhondzadeh S (2011) Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. J Affect Disord 129(1–3):327–331. https://doi.org/10.1016/j.jad.2010.08.015
Andreazza AC, Kapczinski F, Kauer-Sant’Anna M, Walz JC, Bond DJ, Gonçalves CA, Young LT, Yatham LN (2009) 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J Psychiatry Neurosci 34(4):263–271
Ashok AH, Marques TR, Jauhar S, Nour MM, Goodwin GM, Young AH, Howes OD (2017) The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Mol Psychiatry 22(5):666–679. https://doi.org/10.1038/mp.2017.16
American Psychiatric Association. DSM-5 Task Force (2013) Diagnostic and statistical manual of mental disorders: DSM-5, 5th edn. American Psychiatric Association, Washington, DC
Baslow MH (2003) N-acetylaspartate in the vertebrate brain: metabolism and function. Neurochem Res 28(6):941–953. https://doi.org/10.1023/a:1023250721185
Bauer IE, Soares JC, Selek S, Meyer TD (2017) The link between refractoriness and neuroprogression in treatment-resistant bipolar disorder. Mod Trends Pharmacopsychiatry 31:10–26. https://doi.org/10.1159/000470803
Bearden CE, Thompson PM, Dalwani M, Hayashi KM, Lee AD, Nicoletti M, Trakhtenbroit M, Glahn DC, Brambilla P, Sassi RB, Mallinger AG, Frank E, Kupfer DJ, Soares JC (2007) Greater cortical gray matter density in lithium-treated patients with bipolar disorder. Biol Psychiatry 62(1):7–16. https://doi.org/10.1016/j.biopsych.2006.10.027
Bebchuk JM, Arfken CL, Dolan-Manji S, Murphy J, Hasanat K, Manji HK (2000) A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiatry 57(1):95–97. https://doi.org/10.1001/archpsyc.57.1.95
Beneyto M, Kristiansen LV, Oni-Orisan A, McCullumsmith RE, Meador-Woodruff JH (2007) Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 32(9):1888–1902. https://doi.org/10.1038/sj.npp.1301312
Berk M, Dodd S, Kauer-Sant’anna M, Malhi GS, Bourin M, Kapczinski F, Norman T (2007) Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand Suppl 434:41–49. https://doi.org/10.1111/j.1600-0447.2007.01058.x
Berridge MJ (2016) The inositol trisphosphate/calcium signaling pathway in health and disease. Physiol Rev 96(4):1261–1296. https://doi.org/10.1152/physrev.00006.2016
Berridge MJ, Downes CP, Hanley MR (1989) Neural and developmental actions of lithium—a unifying hypothesis. Cell 59(3):411–419. https://doi.org/10.1016/0092-8674(89)90026-3
Bijur GN, De Sarno P, Jope RS (2000) Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium. J Biol Chem 275(11):7583–7590. https://doi.org/10.1074/jbc.275.11.7583
Blumberg HP, Fredericks C, Wang F, Kalmar JH, Spencer L, Papademetris X, Pittman B, Martin A, Peterson BS, Fulbright RK, Krystal JH (2005) Preliminary evidence for persistent abnormalities in amygdala volumes in adolescents and young adults with bipolar disorder. Bipolar Disord 7(6):570–576. https://doi.org/10.1111/j.1399-5618.2005.00264.x
Bolton S, Warner J, Harriss E, Geddes J, Saunders KEA (2020) Bipolar disorder: trimodal age-at-onset distribution. Bipolar Disord. https://doi.org/10.1111/bdi.13016
Bowden CL (2005) A different depression: clinical distinctions between bipolar and unipolar depression. J Affect Disord 84(2–3):117–125. https://doi.org/10.1016/S0165-0327(03)00194-0
Brady RO Jr, McCarthy JM, Prescot AP, Jensen JE, Cooper AJ, Cohen BM, Renshaw PF, Ongur D (2013) Brain gamma-aminobutyric acid (GABA) abnormalities in bipolar disorder. Bipolar Disord 15(4):434–439. https://doi.org/10.1111/bdi.12074
Butler-Munro C, Coddington EJ, Shirley CH, Heyward PM (2010) Lithium modulates cortical excitability in vitro. Brain Res 1352:50–60. https://doi.org/10.1016/j.brainres.2010.07.021
Carpenter C, Sorenson RJ, Jin Y, Klossowski S, Cierpicki T, Gnegy M, Showalter HD (2016) Design and synthesis of triarylacrylonitrile analogues of tamoxifen with improved binding selectivity to protein kinase C. Bioorg Med Chem 24(21):5495–5504. https://doi.org/10.1016/j.bmc.2016.09.002
Carter CJ (2007) Multiple genes and factors associated with bipolar disorder converge on growth factor and stress activated kinase pathways controlling translation initiation: implications for oligodendrocyte viability. Neurochem Int 50(3):461–490. https://doi.org/10.1016/j.neuint.2006.11.009
Casebolt TL, Jope RS (1991) Effects of chronic lithium treatment on protein kinase C and cyclic AMP-dependent protein phosphorylation. Biol Psychiatry 29(3):233–243. https://doi.org/10.1016/0006-3223(91)91285-y
Chen AT, Nasrallah HA (2019) Neuroprotective effects of the second generation antipsychotics. Schizophr Res 208:1–7. https://doi.org/10.1016/j.schres.2019.04.009
Chen CH, Lee CS, Lee MT, Ouyang WC, Chen CC, Chong MY, Wu JY, Tan HK, Lee YC, Chuo LJ, Chiu NY, Tsang HY, Chang TJ, Lung FW, Chiu CH, Chang CH, Chen YS, Hou YM, Chen CC, Lai TJ, Tung CL, Chen CY, Lane HY, Su TP, Feng J, Lin JJ, Chang CJ, Teng PR, Liu CY, Chen CK, Liu IC, Chen JJ, Lu T, Fan CC, Wu CK, Li CF, Wang KH, Wu LS, Peng HL, Chang CP, Lu LS, Chen YT, Cheng AT, Taiwan Bipolar C (2014) Variant GADL1 and response to lithium therapy in bipolar I disorder. N Engl J Med 370(2):119–128. https://doi.org/10.1056/NEJMoa1212444
Chitty KM, Lagopoulos J, Lee RS, Hickie IB, Hermens DF (2013) A systematic review and meta-analysis of proton magnetic resonance spectroscopy and mismatch negativity in bipolar disorder. Eur Neuropsychopharmacol 23(11):1348–1363. https://doi.org/10.1016/j.euroneuro.2013.07.007
Chitty KM, Lagopoulos J, Hickie IB, Hermens DF (2015) Hippocampal glutamatergic/NMDA receptor functioning in bipolar disorder: a study combining mismatch negativity and proton magnetic resonance spectroscopy. Psychiatry Res 233(2):88–94. https://doi.org/10.1016/j.pscychresns.2015.05.002
Chouinard G, Jones BD (1980) Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry 137(1):16–21. https://doi.org/10.1176/ajp.137.1.16
Cousins DA, Squarcina L, Boumezbeur F, Young AH, Bellivier F (2020) Lithium: past, present, and future. Lancet Psychiatry 7(3):222–224. https://doi.org/10.1016/S2215-0366(19)30365-7
Crump C, Sundquist K, Winkleby MA, Sundquist J (2013) Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry 70(9):931–939. https://doi.org/10.1001/jamapsychiatry.2013.1394
Cuellar AK, Johnson SL, Winters R (2005) Distinctions between bipolar and unipolar depression. Clin Psychol Rev 25(3):307–339. https://doi.org/10.1016/j.cpr.2004.12.002
Curran G, Ravindran A (2014) Lithium for bipolar disorder: a review of the recent literature. Expert Rev Neurother 14(9):1079–1098. https://doi.org/10.1586/14737175.2014.947965
da Costa SC, Passos IC, Lowri C, Soares JC, Kapczinski F (2016) Refractory bipolar disorder and neuroprogression. Prog Neuropsychopharmacol Biol Psychiatry 70:103–110. https://doi.org/10.1016/j.pnpbp.2015.09.005
Dickson EJ, Hille B (2019) Understanding phosphoinositides: rare, dynamic, and essential membrane phospholipids. Biochem J 476(1):1–23. https://doi.org/10.1042/bcj20180022
Dodd S, Maes M, Anderson G, Dean OM, Moylan S, Berk M (2013) Putative neuroprotective agents in neuropsychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 42:135–145. https://doi.org/10.1016/j.pnpbp.2012.11.007
Dols A, Beekman A (2018) Older age bipolar disorder. Psychiatr Clin N Am 41(1):95–110. https://doi.org/10.1016/j.psc.2017.10.008
Dorph-Petersen KA, Pierri JN, Perel JM, Sun Z, Sampson AR, Lewis DA (2005) The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology 30(9):1649–1661. https://doi.org/10.1038/sj.npp.1300710
Epand RM (2017) Features of the phosphatidylinositol cycle and its role in signal transduction. J Membr Biol 250(4):353–366. https://doi.org/10.1007/s00232-016-9909-y
Espanhol JCL, Vieira-Coelho MA (2021) Effects of lithium use on the white matter of patients with bipolar disorder—a systematic review. Nord J Psychiatry. https://doi.org/10.1080/08039488.2021.1921264
Fan AH, Hassell J (2008) Bipolar disorder and comorbid personality psychopathology: a review of the literature. J Clin Psychiatry 69(11):1794–1803. https://doi.org/10.4088/jcp.v69n1115
Fatemi SH, Folsom TD (2009) The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull 35(3):528–548. https://doi.org/10.1093/schbul/sbn187
Ferrie LJ, Gartside SE, Martin KM, Young AH, McQuade R (2008) Effect of chronic lithium treatment on D2/3 autoreceptor regulation of dopaminergic function in the rat. Pharmacol Biochem Behav 90(2):218–225. https://doi.org/10.1016/j.pbb.2007.10.013
Frey BN, Zunta-Soares GB, Caetano SC, Nicoletti MA, Hatch JP, Brambilla P, Mallinger AG, Soares JC (2008) Illness duration and total brain gray matter in bipolar disorder: evidence for neurodegeneration? Eur Neuropsychopharmacol 18(10):717–722. https://doi.org/10.1016/j.euroneuro.2008.04.015
Friedman E, Hoau Yan W, Levinson D, Connell TA, Singh H (1993) Altered platelet protein kinase C activity in bipolar affective disorder, manic episode. Biol Psychiatry 33(7):520–525. https://doi.org/10.1016/0006-3223(93)90006-y
Fries GR, Pfaffenseller B, Stertz L, Paz AV, Dargél AA, Kunz M, Kapczinski F (2012) Staging and neuroprogression in bipolar disorder. Curr Psychiatry Rep 14(6):667–675. https://doi.org/10.1007/s11920-012-0319-2
Fritz K, Russell AMT, Allwang C, Kuiper S, Lampe L, Malhi GS (2017) Is a delay in the diagnosis of bipolar disorder inevitable? Bipolar Disord 19(5):396–400. https://doi.org/10.1111/bdi.12499
Fukumoto T, Morinobu S, Okamoto Y, Kagaya A, Yamawaki S (2001) Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology 158(1):100–106. https://doi.org/10.1007/s002130100871
Fusar-Poli P, Salazar de Pablo G, Correll CU, Meyer-Lindenberg A, Millan MJ, Borgwardt S, Galderisi S, Bechdolf A, Pfennig A, Kessing LV, van Amelsvoort T, Nieman DH, Domschke K, Krebs MO, Koutsouleris N, McGuire P, Do KQ, Arango C (2020) Prevention of psychosis: advances in detection, prognosis, and intervention. JAMA Psychiatry 77(7):755–765. https://doi.org/10.1001/jamapsychiatry.2019.4779
Geddes JR, Miklowitz DJ (2013) Treatment of bipolar disorder. Lancet 381(9878):1672–1682. https://doi.org/10.1016/S0140-6736(13)60857-0
Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM (2004) Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 161(2):217–222. https://doi.org/10.1176/appi.ajp.161.2.217
Germana C, Kempton MJ, Sarnicola A, Christodoulou T, Haldane M, Hadjulis M, Girardi P, Tatarelli R, Frangou S (2010) The effects of lithium and anticonvulsants on brain structure in bipolar disorder. Acta Psychiatr Scand 122(6):481–487. https://doi.org/10.1111/j.1600-0447.2010.01582.x
Goff DC, Falkai P, Fleischhacker WW, Girgis RR, Kahn RM, Uchida H, Zhao J, Lieberman JA (2017) The long-term effects of antipsychotic medication on clinical course in Schizophrenia. Am J Psychiatry 174(9):840–849. https://doi.org/10.1176/appi.ajp.2017.16091016
Goodwin FK (2002) Rationale for long-term treatment of bipolar disorder and evidence for long-term lithium treatment. J Clin Psychiatry 63(Suppl 10):5–12
Goodwin FK, Jamison KR (1990) Manic-depressive illness. Oxford University Press, New York
Gordovez FJA, McMahon FJ (2020) The genetics of bipolar disorder. Mol Psychiatry 25(3):544–559. https://doi.org/10.1038/s41380-019-0634-7
Gotzsche PC, Young AH, Crace J (2015) Does long term use of psychiatric drugs cause more harm than good? BMJ 350:h2435. https://doi.org/10.1136/bmj.h2435
Graham RK, Tavella G, Parker GB (2018) Is there consensus across international evidence-based guidelines for the psychotropic drug management of bipolar disorder during the perinatal period? J Affect Disord 228:216–221. https://doi.org/10.1016/j.jad.2017.12.022
Grande I, Magalhães PV, Chendo I, Stertz L, Panizutti B, Colpo GD, Rosa AR, Gama CS, Kapczinski F, Vieta E (2014) Staging bipolar disorder: clinical, biochemical, and functional correlates. Acta Psychiatr Scand 129(6):437–444. https://doi.org/10.1111/acps.12268
Grof P, Alda M, Grof E, Fox D, Cameron P (1993) The challenge of predicting response to stabilising lithium treatment. The importance of patient selection. Br J Psychiatry Suppl 21:16–19
Gunosewoyo H, Yu L, Munoz L, Kassiou M (2017) Kinase targets in CNS drug discovery. Future Med Chem 9(3):303–314. https://doi.org/10.4155/fmc-2016-0214
Hafeman DM, Chang KD, Garrett AS, Sanders EM, Phillips ML (2012) Effects of medication on neuroimaging findings in bipolar disorder: an updated review. Bipolar Disord 14(4):375–410. https://doi.org/10.1111/j.1399-5618.2012.01023.x
Hafeman DM, Rooks B, Merranko J, Liao F, Gill MK, Goldstein TR, Diler R, Ryan N, Goldstein BI, Axelson DA, Strober M, Keller M, Hunt J, Hower H, Weinstock LM, Yen S, Birmaher B (2019) Lithium versus other mood-stabilizing medications in a longitudinal study of youth diagnosed with Bipolar. J Am Acad Child Adolesc Psychiatry 59(10):1146–1555. https://doi.org/10.1016/j.jaac.2019.06.013
Haggarty SJ, Karmacharya R, Perlis RH (2021) Advances toward precision medicine for bipolar disorder: mechanisms & molecules. Mol Psychiatry 26(1):168–185. https://doi.org/10.1038/s41380-020-0831-4
Haijma SV, Van Haren N, Cahn W, Koolschijn PC, Hulshoff Pol HE, Kahn RS (2013) Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects. Schizophr Bull 39(5):1129–1138. https://doi.org/10.1093/schbul/sbs118
Hajek T, Bauer M, Pfennig A, Cullis J, Ploch J, O’Donovan C, Bohner G, Klingebiel R, Young LT, Macqueen GM, Alda M (2012a) Large positive effect of lithium on prefrontal cortex N-acetylaspartate in patients with bipolar disorder: 2-centre study. J Psychiatry Neurosci 37(3):185–192. https://doi.org/10.1503/jpn.110097
Hajek T, Cullis J, Novak T, Kopecek M, Hoschl C, Blagdon R, O’Donovan C, Bauer M, Young LT, Macqueen G, Alda M (2012b) Hippocampal volumes in bipolar disorders: opposing effects of illness burden and lithium treatment. Bipolar Disord 14(3):261–270. https://doi.org/10.1111/j.1399-5618.2012.01013.x
Hajek T, Bauer M, Simhandl C, Rybakowski J, O’Donovan C, Pfennig A, Konig B, Suwalska A, Yucel K, Uher R, Young LT, MacQueen G, Alda M (2014) Neuroprotective effect of lithium on hippocampal volumes in bipolar disorder independent of long-term treatment response. Psychol Med 44(3):507–517. https://doi.org/10.1017/S0033291713001165
Harrison PJ, Colbourne L, Harrison CH (2020) The neuropathology of bipolar disorder: systematic review and meta-analysis. Mol Psychiatry 25(8):1787–1808. https://doi.org/10.1038/s41380-018-0213-3
Harwood AJ (2005) Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited. Mol Psychiatry 10(1):117–126. https://doi.org/10.1038/sj.mp.4001618
Hashimoto K, Shimizu E, Iyo M (2004) Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Brain Res Rev 45(2):104–114. https://doi.org/10.1016/j.brainresrev.2004.02.003
Hibar DP, Westlye LT, van Erp TG, Rasmussen J, Leonardo CD, Faskowitz J, Haukvik UK, Hartberg CB, Doan NT, Agartz I, Dale AM, Gruber O, Kramer B, Trost S, Liberg B, Abe C, Ekman CJ, Ingvar M, Landen M, Fears SC, Freimer NB, Bearden CE, Costa Rica/Colombia Consortium for Genetic Investigation of Bipolar E, Sprooten E, Glahn DC, Pearlson GD, Emsell L, Kenney J, Scanlon C, McDonald C, Cannon DM, Almeida J, Versace A, Caseras X, Lawrence NS, Phillips ML, Dima D, Delvecchio G, Frangou S, Satterthwaite TD, Wolf D, Houenou J, Henry C, Malt UF, Boen E, Elvsashagen T, Young AH, Lloyd AJ, Goodwin GM, Mackay CE, Bourne C, Bilderbeck A, Abramovic L, Boks MP, van Haren NE, Ophoff RA, Kahn RS, Bauer M, Pfennig A, Alda M, Hajek T, Mwangi B, Soares JC, Nickson T, Dimitrova R, Sussmann JE, Hagenaars S, Whalley HC, McIntosh AM, Thompson PM, Andreassen OA (2016) Subcortical volumetric abnormalities in bipolar disorder. Mol Psychiatry 21(12):1710–1716. https://doi.org/10.1038/mp.2015.227
Hibar DP, Westlye LT, Doan NT, Jahanshad N, Cheung JW, Ching CRK, Versace A, Bilderbeck AC, Uhlmann A, Mwangi B, Kramer B, Overs B, Hartberg CB, Abe C, Dima D, Grotegerd D, Sprooten E, Boen E, Jimenez E, Howells FM, Delvecchio G, Temmingh H, Starke J, Almeida JRC, Goikolea JM, Houenou J, Beard LM, Rauer L, Abramovic L, Bonnin M, Ponteduro MF, Keil M, Rive MM, Yao N, Yalin N, Najt P, Rosa PG, Redlich R, Trost S, Hagenaars S, Fears SC, Alonso-Lana S, van Erp TGM, Nickson T, Chaim-Avancini TM, Meier TB, Elvsashagen T, Haukvik UK, Lee WH, Schene AH, Lloyd AJ, Young AH, Nugent A, Dale AM, Pfennig A, McIntosh AM, Lafer B, Baune BT, Ekman CJ, Zarate CA, Bearden CE, Henry C, Simhandl C, McDonald C, Bourne C, Stein DJ, Wolf DH, Cannon DM, Glahn DC, Veltman DJ, Pomarol-Clotet E, Vieta E, Canales-Rodriguez EJ, Nery FG, Duran FLS, Busatto GF, Roberts G, Pearlson GD, Goodwin GM, Kugel H, Whalley HC, Ruhe HG, Soares JC, Fullerton JM, Rybakowski JK, Savitz J, Chaim KT, Fatjo-Vilas M, Soeiro-de-Souza MG, Boks MP, Zanetti MV, Otaduy MCG, Schaufelberger MS, Alda M, Ingvar M, Phillips ML, Kempton MJ, Bauer M, Landen M, Lawrence NS, van Haren NEM, Horn NR, Freimer NB, Gruber O, Schofield PR, Mitchell PB, Kahn RS, Lenroot R, Machado-Vieira R, Ophoff RA, Sarro S, Frangou S, Satterthwaite TD, Hajek T, Dannlowski U, Malt UF, Arolt V, Gattaz WF, Drevets WC, Caseras X, Agartz I, Thompson PM, Andreassen OA (2018) Cortical abnormalities in bipolar disorder: an MRI analysis of 6503 individuals from the ENIGMA Bipolar Disorder Working Group. Mol Psychiatry 23(4):932–942. https://doi.org/10.1038/mp.2017.73
Hirschfeld RM, Calabrese JR, Weissman MM, Reed M, Davies MA, Frye MA, Keck PE Jr, Lewis L, McElroy SL, McNulty JP, Wagner KD (2003) Screening for bipolar disorder in the community. J Clin Psychiatry 64(1):53–59. https://doi.org/10.4088/jcp.v64n0111
Iwahashi K, Nishizawa D, Narita S, Numajiri M, Murayama O, Yoshihara E, Onozawa Y, Nagahori K, Fukamauchi F, Ikeda K, Ishigooka J (2014) Haplotype analysis of GSK-3beta gene polymorphisms in bipolar disorder lithium responders and nonresponders. Clin Neuropharmacol 37(4):108–110. https://doi.org/10.1097/WNF.0000000000000039
Jope RS, Song L, Li PP, Young LT, Kish SJ, Pacheco MA, Warsh JJ (1996) The phosphoinositide signal transduction system is impaired in bipolar affective disorder brain. J Neurochem 66(6):2402–2409. https://doi.org/10.1046/j.1471-4159.1996.66062402.x
Kapczinski F, Magalhães PV, Balanzá-Martinez V, Dias VV, Frangou S, Gama CS, Gonzalez-Pinto A, Grande I, Ha K, Kauer-Sant’Anna M, Kunz M, Kupka R, Leboyer M, Lopez-Jaramillo C, Post RM, Rybakowski JK, Scott J, Strejilevitch S, Tohen M, Vazquez G, Yatham L, Vieta E, Berk M (2014) Staging systems in bipolar disorder: an International Society for Bipolar Disorders Task Force Report. Acta Psychiatr Scand 130(5):354–363. https://doi.org/10.1111/acps.12305
Kapczinski NS, Mwangi B, Cassidy RM, Librenza-Garcia D, Bermudez MB, Kauer-Sant’anna M, Kapczinski F, Passos IC (2017) Neuroprogression and illness trajectories in bipolar disorder. Expert Rev Neurother 17(3):277–285. https://doi.org/10.1080/14737175.2017.1240615
Kato T, Shioiri T, Takahashi S, Inubushi T (1991) Measurement of brain phosphoinositide metabolism in bipolar patients using in vivo 31P-MRS. J Affect Disord 22(4):185–190. https://doi.org/10.1016/0165-0327(91)90064-y
Kempton MJ, Salvador Z, Munafo MR, Geddes JR, Simmons A, Frangou S, Williams SC (2011) Structural neuroimaging studies in major depressive disorder. Meta-analysis and comparison with bipolar disorder. Arch Gen Psychiatry 68(7):675–690. https://doi.org/10.1001/archgenpsychiatry.2011.60
Kessing LV, Vradi E, Andersen PK (2014) Starting lithium prophylaxis early v. late in bipolar disorder. Br J Psychiatry 205(3):214–220. https://doi.org/10.1192/bjp.bp.113.142802
Kessing LV, Vradi E, Andersen PK (2016) Nationwide and population-based prescription patterns in bipolar disorder. Bipolar Disord 18(2):174–182. https://doi.org/10.1111/bdi.12371
King TD, Bijur GN, Jope RS (2001) Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3beta and attenuated by lithium. Brain Res 919(1):106–114. https://doi.org/10.1016/s0006-8993(01)03005-0
Klein PS, Melton DA (1996) A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 93(16):8455–8459. https://doi.org/10.1073/pnas.93.16.8455
Knott S, Forty L, Craddock N, Thomas RH (2015) Epilepsy and bipolar disorder. Epilepsy Behav 52(Pt A):267–274. https://doi.org/10.1016/j.yebeh.2015.07.003
Konopaske GT, Lange N, Coyle JT, Benes FM (2014) Prefrontal cortical dendritic spine pathology in schizophrenia and bipolar disorder. JAMA Psychiatry 71(12):1323–1331. https://doi.org/10.1001/jamapsychiatry.2014.1582
Kovács P, Hernádi I (2002) Iontophoresis of lithium antagonizes noradrenergic action on prefrontal neurons of the rat. Brain Res 947(1):150–156. https://doi.org/10.1016/s0006-8993(02)03150-5
Kubota M, van Haren NE, Haijma SV, Schnack HG, Cahn W, Hulshoff Pol HE, Kahn RS (2015) Association of IQ changes and progressive brain changes in patients with Schizophrenia. JAMA Psychiatry 72(8):803–812. https://doi.org/10.1001/jamapsychiatry.2015.0712
Kupka RW, Altshuler LL, Nolen WA, Suppes T, Luckenbaugh DA, Leverich GS, Frye MA, Keck PE Jr, McElroy SL, Grunze H, Post RM (2007) Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord 9(5):531–535. https://doi.org/10.1111/j.1399-5618.2007.00467.x
Leboyer M, Soreca I, Scott J, Frye M, Henry C, Tamouza R, Kupfer DJ (2012) Can bipolar disorder be viewed as a multi-system inflammatory disease? J Affect Disord 141(1):1–10. https://doi.org/10.1016/j.jad.2011.12.049
Leopold K, Becker T, Förstl J, Kiefer F, de Millas W, Janetzky W, Lambert M, Pfennig A, Bechdolf A (2020) Early intervention in Schizophrenia—an update. Fortschr Neurol Psychiatr 88(6):387–397. https://doi.org/10.1055/a-0918-6071
Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373(9657):31–41. https://doi.org/10.1016/s0140-6736(08)61764-x
Levin FR, Hennessy G (2004) Bipolar disorder and substance abuse. Biol Psychiatry 56(10):738–748. https://doi.org/10.1016/j.biopsych.2004.05.008
Licht RW (2012) Lithium: still a major option in the management of bipolar disorder. CNS Neurosci Ther 18(3):219–226. https://doi.org/10.1111/j.1755-5949.2011.00260.x
Lish JD, Dime-Meenan S, Whybrow PC, Price RA, Hirschfeld RM (1994) The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members. J Affect Disord 31(4):281–294. https://doi.org/10.1016/0165-0327(94)90104-x
Lubrich B, van Calker D (1999) Inhibition of the high affinity myo-inositol transport system: a common mechanism of action of antibipolar drugs? Neuropsychopharmacology 21(4):519–529. https://doi.org/10.1016/S0893-133X(99)00037-8
Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J (2001) Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 20(1–2):27–39. https://doi.org/10.1093/emboj/20.1.27
Lyoo IK, Sung YH, Dager SR, Friedman SD, Lee JY, Kim SJ, Kim N, Dunner DL, Renshaw PF (2006) Regional cerebral cortical thinning in bipolar disorder. Bipolar Disord 8(1):65–74. https://doi.org/10.1111/j.1399-5618.2006.00284.x
Lyoo IK, Dager SR, Kim JE, Yoon SJ, Friedman SD, Dunner DL, Renshaw PF (2010) Lithium-induced gray matter volume increase as a neural correlate of treatment response in bipolar disorder: a longitudinal brain imaging study. Neuropsychopharmacology 35(8):1743–1750. https://doi.org/10.1038/npp.2010.41
Machado-Vieira R, Dietrich MO, Leke R, Cereser VH, Zanatto V, Kapczinski F, Souza DO, Portela LV, Gentil V (2007) Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol Psychiatry 61(2):142–144. https://doi.org/10.1016/j.biopsych.2006.03.070
Maisonpierre PC, Le Beau MM, Espinosa R 3rd, Ip NY, Belluscio L, de la Monte SM, Squinto S, Furth ME, Yancopoulos GD (1991) Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizations. Genomics 10(3):558–568. https://doi.org/10.1016/0888-7543(91)90436-i
Malhi GS, Tanious M, Das P, Coulston CM, Berk M (2013) Potential mechanisms of action of lithium in bipolar disorder. Current understanding. CNS Drugs 27(2):135–153. https://doi.org/10.1007/s40263-013-0039-0
Manji HK, Moore GJ, Chen G (2000) Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. J Clin Psychiatry 61(Suppl 9):82–96
Manning JS, Connor PD, Sahai A (1998) The bipolar spectrum: a review of current concepts and implications for the management of depression in primary care. Arch Fam Med 7(1):63–71. https://doi.org/10.1001/archfami.7.1.63
Masaki C, Sharpley AL, Godlewska BR, Berrington A, Hashimoto T, Singh N, Vasudevan SR, Emir UE, Churchill GC, Cowen PJ (2016) Effects of the potential lithium-mimetic, ebselen, on brain neurochemistry: a magnetic resonance spectroscopy study at 7 tesla. Psychopharmacology 233(6):1097–1104. https://doi.org/10.1007/s00213-015-4189-2
McCullumsmith RE, Kristiansen LV, Beneyto M, Scarr E, Dean B, Meador-Woodruff JH (2007) Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. Brain Res 1127(1):108–118. https://doi.org/10.1016/j.brainres.2006.09.011
Moore GJ, Bebchuk JM, Parrish JK, Faulk MW, Arfken CL, Strahl-Bevacqua J, Manji HK (1999) Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness. Am J Psychiatry 156(12):1902–1908. https://doi.org/10.1176/ajp.156.12.1902
Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK (2000) Lithium-induced increase in human brain grey matter. Lancet 356(9237):1241–1242. https://doi.org/10.1016/s0140-6736(00)02793-8
Moore GJ, Cortese BM, Glitz DA, Zajac-Benitez C, Quiroz JA, Uhde TW, Drevets WC, Manji HK (2009) A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. J Clin Psychiatry 70(5):699–705. https://doi.org/10.4088/JCP.07m03745
Motoi Y, Shimada K, Ishiguro K, Hattori N (2014) Lithium and autophagy. ACS Chem Neurosci 5(6):434–442. https://doi.org/10.1021/cn500056q
Muller P, Seeman P (1977) Brain neurotransmitter receptors after long-term haloperidol: dopamine, acetylcholine, serotonin, alpha-noradrenergic and naloxone receptors. Life Sci 21(12):1751–1758. https://doi.org/10.1016/0024-3205(77)90155-2
Murray RM, Lewis SW (1987) Is schizophrenia a neurodevelopmental disorder? Br Med J 295(6600):681–682. https://doi.org/10.1136/bmj.295.6600.681
Neves-Pereira M, Mundo E, Muglia P, King N, Macciardi F, Kennedy JL (2002) The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. Am J Hum Genet 71(3):651–655. https://doi.org/10.1086/342288
NICE (2014) Bipoiar disorder: assessment and management. https://www.niceorguk/guidance/cg185. Accessed Sept 2020
Niciu MJ, Ionescu DF, Mathews DC, Richards EM, Zarate CA Jr (2013) Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part I: major depressive disorder. CNS Spectr 18(5):231–241. https://doi.org/10.1017/s1092852913000059
Nortje G, Stein DJ, Radua J, Mataix-Cols D, Horn N (2013) Systematic review and voxel-based meta-analysis of diffusion tensor imaging studies in bipolar disorder. J Affect Disord 150(2):192–200. https://doi.org/10.1016/j.jad.2013.05.034
Novick AM, Scott AT, Neill Epperson C, Schneck CD (2020) Neuropsychiatric effects of tamoxifen: Challenges and opportunities. Front Neuroendocrinol 59:100869. https://doi.org/10.1016/j.yfrne.2020.100869
Novotny E, Ashwal S, Shevell M (1998) Proton magnetic resonance spectroscopy: an emerging technology in pediatric neurology research. Pediatr Res 44(1):1–10. https://doi.org/10.1203/00006450-199807000-00001
Pacheco MA, Jope RS (1996) Phosphoinositide signaling in human brain. Prog Neurobiol 50(2–3):255–273. https://doi.org/10.1016/s0301-0082(96)00035-4
Palacios J, Yildiz A, Young AH, Taylor MJ (2019) Tamoxifen for bipolar disorder: systematic review and meta-analysis. J Psychopharmacol 33(2):177–184. https://doi.org/10.1177/0269881118822167
Passos IC, Mwangi B, Vieta E, Berk M, Kapczinski F (2016) Areas of controversy in neuroprogression in bipolar disorder. Acta Psychiatr Scand 134(2):91–103. https://doi.org/10.1111/acps.12581
Perlis RH (2005) Misdiagnosis of bipolar disorder. Am J Manag Care 11(9 Suppl):S271-274
Pfennig A, Leopold K, Martini J, Boehme A, Lambert M, Stamm T, Bermpohl F, Reif A, Kittel-Schneider S, Juckel G, Fallgatter AJ, Kircher T, Jansen A, Pfeiffer S, Berndt C, Rottmann-Wolf M, Sauer C, Ritter P, Correll CU, Bechdolf A, Falkenberg I, Bauer M (2020) Improving early recognition and intervention in people at increased risk for the development of bipolar disorder: study protocol of a prospective-longitudinal, naturalistic cohort study (Early-BipoLife). Int J Bipolar Disord 8(1):22. https://doi.org/10.1186/s40345-020-00183-4
Rapoport JL, Giedd JN, Gogtay N (2012) Neurodevelopmental model of schizophrenia: update 2012. Mol Psychiatry 17(12):1228–1238. https://doi.org/10.1038/mp.2012.23
Ratheesh A, Cotton SM, Davey CG, Adams S, Bechdolf A, Macneil C, Berk M, McGorry PD (2017) Ethical considerations in preventive interventions for bipolar disorder. Early Interv Psychiatry 11(2):104–112. https://doi.org/10.1111/eip.12340
Rosenberg G (2007) The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell Mol Life Sci 64(16):2090–2103. https://doi.org/10.1007/s00018-007-7079-x
Rosse C, Linch M, Kermorgant S, Cameron AJ, Boeckeler K, Parker PJ (2010) PKC and the control of localized signal dynamics. Nat Rev Mol Cell Biol 11(2):103–112. https://doi.org/10.1038/nrm2847
Sanches M, Keshavan MS, Brambilla P, Soares JC (2008) Neurodevelopmental basis of bipolar disorder: a critical appraisal. Prog Neuropsychopharmacol Biol Psychiatry 32(7):1617–1627. https://doi.org/10.1016/j.pnpbp.2008.04.017
Saxena A, Scaini G, Bavaresco DV, Leite C, Valvassori SS, Carvalho AF, Quevedo J (2017) Role of protein kinase C in bipolar disorder: a review of the current literature. Mol Neuropsychiatry 3(2):108–124. https://doi.org/10.1159/000480349
Scearce-Levie K, Sanchez PE, Lewcock JW (2020) Leveraging preclinical models for the development of Alzheimer disease therapeutics. Nat Rev Drug Discov 19(7):447–462. https://doi.org/10.1038/s41573-020-0065-9
Scola G, Andreazza AC (2015) The role of neurotrophins in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 56:122–128. https://doi.org/10.1016/j.pnpbp.2014.08.013
Severus E, Taylor MJ, Sauer C, Pfennig A, Ritter P, Bauer M, Geddes JR (2014) Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int J Bipolar Disord 2:15. https://doi.org/10.1186/s40345-014-0015-8
Sharpley AL, Williams C, Holder AA, Godlewska BR, Singh N, Shanyinde M, MacDonald O, Cowen PJ (2020) A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania. Psychopharmacology 237(12):3773–3782. https://doi.org/10.1007/s00213-020-05654-1
Sherwood Brown E, Suppes T, Adinoff B, Rajan Thomas N (2001) Drug abuse and bipolar disorder: comorbidity or misdiagnosis? J Affect Disord 65(2):105–115. https://doi.org/10.1016/s0165-0327(00)00169-5
Simmons ML, Frondoza CG, Coyle JT (1991) Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 45(1):37–45. https://doi.org/10.1016/0306-4522(91)90101-s
Singh N, Halliday AC, Thomas JM, Kuznetsova OV, Baldwin R, Woon EC, Aley PK, Antoniadou I, Sharp T, Vasudevan SR, Churchill GC (2013) A safe lithium mimetic for bipolar disorder. Nat Commun 4:1332. https://doi.org/10.1038/ncomms2320
Singh N, Sharpley AL, Emir UE, Masaki C, Herzallah MM, Gluck MA, Sharp T, Harmer CJ, Vasudevan SR, Cowen PJ, Churchill GC (2016) Effect of the putative lithium mimetic ebselen on brain myo-inositol, sleep, and emotional processing in humans. Neuropsychopharmacology 41(7):1768–1778. https://doi.org/10.1038/npp.2015.343
Sklar P, Gabriel SB, McInnis MG, Bennett P, Lim Y, Tsan G, Schaffner S, Kirov G, Jones I, Owen M, Craddock N, DePaulo JR, Lander ES (2002) Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Brain-derived neutrophic factor. Mol Psychiatry 7(6):579–593. https://doi.org/10.1038/sj.mp.4001058
Stahl EA, Breen G, Forstner AJ, McQuillin A, Ripke S, Trubetskoy V, Mattheisen M, Wang Y, Coleman JRI, Gaspar HA, de Leeuw CA, Steinberg S, Pavlides JMW, Trzaskowski M, Byrne EM, Pers TH, Holmans PA, Richards AL, Abbott L, Agerbo E, Akil H, Albani D, Alliey-Rodriguez N, Als TD, Anjorin A, Antilla V, Awasthi S, Badner JA, Baekvad-Hansen M, Barchas JD, Bass N, Bauer M, Belliveau R, Bergen SE, Pedersen CB, Boen E, Boks MP, Boocock J, Budde M, Bunney W, Burmeister M, Bybjerg-Grauholm J, Byerley W, Casas M, Cerrato F, Cervantes P, Chambert K, Charney AW, Chen D, Churchhouse C, Clarke TK, Coryell W, Craig DW, Cruceanu C, Curtis D, Czerski PM, Dale AM, de Jong S, Degenhardt F, Del-Favero J, DePaulo JR, Djurovic S, Dobbyn AL, Dumont A, Elvsashagen T, Escott-Price V, Fan CC, Fischer SB, Flickinger M, Foroud TM, Forty L, Frank J, Fraser C, Freimer NB, Frisen L, Gade K, Gage D, Garnham J, Giambartolomei C, Pedersen MG, Goldstein J, Gordon SD, Gordon-Smith K, Green EK, Green MJ, Greenwood TA, Grove J, Guan W, Guzman-Parra J, Hamshere ML, Hautzinger M, Heilbronner U, Herms S, Hipolito M, Hoffmann P, Holland D, Huckins L, Jamain S, Johnson JS, Jureus A, Kandaswamy R, Karlsson R, Kennedy JL, Kittel-Schneider S, Knowles JA, Kogevinas M, Koller AC, Kupka R, Lavebratt C, Lawrence J, Lawson WB, Leber M, Lee PH, Levy SE, Li JZ, Liu C, Lucae S, Maaser A, MacIntyre DJ, Mahon PB, Maier W, Martinsson L, McCarroll S, McGuffin P, McInnis MG, McKay JD, Medeiros H, Medland SE, Meng F, Milani L, Montgomery GW, Morris DW, Muhleisen TW, Mullins N, Nguyen H, Nievergelt CM, Adolfsson AN, Nwulia EA, O’Donovan C, Loohuis LMO, Ori APS, Oruc L, Osby U, Perlis RH, Perry A, Pfennig A, Potash JB, Purcell SM, Regeer EJ, Reif A, Reinbold CS, Rice JP, Rivas F, Rivera M, Roussos P, Ruderfer DM, Ryu E, Sanchez-Mora C, Schatzberg AF, Scheftner WA, Schork NJ, Shannon Weickert C, Shehktman T, Shilling PD, Sigurdsson E, Slaney C, Smeland OB, Sobell JL, Soholm Hansen C, Spijker AT, St Clair D, Steffens M, Strauss JS, Streit F, Strohmaier J, Szelinger S, Thompson RC, Thorgeirsson TE, Treutlein J, Vedder H, Wang W, Watson SJ, Weickert TW, Witt SH, Xi S, Xu W, Young AH, Zandi P, Zhang P, Zollner S, e QC, Consortium B, Adolfsson R, Agartz I, Alda M, Backlund L, Baune BT, Bellivier F, Berrettini WH, Biernacka JM, Blackwood DHR, Boehnke M, Borglum AD, Corvin A, Craddock N, Daly MJ, Dannlowski U, Esko T, Etain B, Frye M, Fullerton JM, Gershon ES, Gill M, Goes F, Grigoroiu-Serbanescu M, Hauser J, Hougaard DM, Hultman CM, Jones I, Jones LA, Kahn RS, Kirov G, Landen M, Leboyer M, Lewis CM, Li QS, Lissowska J, Martin NG, Mayoral F, McElroy SL, McIntosh AM, McMahon FJ, Melle I, Metspalu A, Mitchell PB, Morken G, Mors O, Mortensen PB, Muller-Myhsok B, Myers RM, Neale BM, Nimgaonkar V, Nordentoft M, Nothen MM, O’Donovan MC, Oedegaard KJ, Owen MJ, Paciga SA, Pato C, Pato MT, Posthuma D, Ramos-Quiroga JA, Ribases M, Rietschel M, Rouleau GA, Schalling M, Schofield PR, Schulze TG, Serretti A, Smoller JW, Stefansson H, Stefansson K, Stordal E, Sullivan PF, Turecki G, Vaaler AE, Vieta E, Vincent JB, Werge T, Nurnberger JI, Wray NR, Di Florio A, Edenberg HJ, Cichon S, Ophoff RA, Scott LJ, Andreassen OA, Kelsoe J, Sklar P, Bipolar Disorder Working Group of the Psychiatric Genomics C (2019) Genome-wide association study identifies 30 loci associated with bipolar disorder. Nat Genet 51(5):793–803. https://doi.org/10.1038/s41588-019-0397-8
Sun YR, Herrmann N, Scott CJM, Black SE, Khan MM, Lanctot KL (2018) Global grey matter volume in adult bipolar patients with and without lithium treatment: a meta-analysis. J Affect Disord 225:599–606. https://doi.org/10.1016/j.jad.2017.08.078
Talaei A, Pourgholami M, Khatibi-Moghadam H, Faridhosseini F, Farhoudi F, Askari-Noghani A, Sadeghi R (2016) Tamoxifen: a protein kinase C inhibitor to treat mania: a systematic review and meta-analysis of randomized, placebo-controlled trials. J Clin Psychopharmacol 36(3):272–275. https://doi.org/10.1097/JCP.0000000000000492
Teixeira AL, Colpo GD, Fries GR, Bauer IE, Selvaraj S (2019) Biomarkers for bipolar disorder: current status and challenges ahead. Expert Rev Neurother 19(1):67–81. https://doi.org/10.1080/14737175.2019.1550361
Tighe SK, Mahon PB, Potash JB (2011) Predictors of lithium response in bipolar disorder. Ther Adv Chronic Dis 2(3):209–226. https://doi.org/10.1177/2040622311399173
Toker L, Mancarci BO, Tripathy S, Pavlidis P (2018) Transcriptomic evidence for alterations in astrocytes and parvalbumin interneurons in subjects with Bipolar Disorder and Schizophrenia. Biol Psychiatry 84(11):787–796. https://doi.org/10.1016/j.biopsych.2018.07.010
Uribe E, Wix R (2012) Neuronal migration, apoptosis and bipolar disorder. Rev Psiquiatr Salud Ment 5(2):127–133. https://doi.org/10.1016/j.rpsm.2011.11.005
Vajda FJ (2002) Neuroprotection and neurodegenerative disease. J Clin Neurosci 9(1):4–8. https://doi.org/10.1054/jocn.2001.1027
Valli I, Fabbri C, Young AH (2019) Uncovering neurodevelopmental features in bipolar affective disorder. Br J Psychiatry 215(1):383–385. https://doi.org/10.1192/bjp.2019.117
van Calker D, Belmaker RH (2000) The high affinity inositol transport system–implications for the pathophysiology and treatment of bipolar disorder. Bipolar Disord 2(2):102–107. https://doi.org/10.1034/j.1399-5618.2000.020203.x
van der Markt A, Klumpers UMH, Dols A, Draisma S, Boks MP, van Bergen A, Ophoff RA, Beekman ATF, Kupka RW (2020) Exploring the clinical utility of two staging models for bipolar disorder. Bipolar Disord 22(1):38–45. https://doi.org/10.1111/bdi.12825
Vieta E, Reinares M, Rosa AR (2011) Staging bipolar disorder. Neurotox Res 19(2):279–285. https://doi.org/10.1007/s12640-010-9197-8
Wang HY, Friedman E (1989) Lithium inhibition of protein kinase C activation-induced serotonin release. Psychopharmacology 99(2):213–218. https://doi.org/10.1007/BF00442810
Wang AY, Lohmann KM, Yang CK, Zimmerman EI, Pantazopoulos H, Herring N, Berretta S, Heckers S, Konradi C (2011) Bipolar disorder type 1 and schizophrenia are accompanied by decreased density of parvalbumin- and somatostatin-positive interneurons in the parahippocampal region. Acta Neuropathol 122(5):615–626. https://doi.org/10.1007/s00401-011-0881-4
Wetsel WC, Khan WA, Merchenthaler I, Rivera H, Halpern AE, Phung HM, Negro-Vilar A, Hannun YA (1992) Tissue and cellular distribution of the extended family of protein kinase C isoenzymes. J Cell Biol 117(1):121–133. https://doi.org/10.1083/jcb.117.1.121
Williams RSB, Cheng LL, Mudge AW, Harwood AJ (2002) A common mechanism of action for three mood-stabilizing drugs. Nature 417(6886):292–295. https://doi.org/10.1038/417292a
Wise T, Radua J, Nortje G, Cleare AJ, Young AH, Arnone D (2016) Voxel-based meta-analytical evidence of structural disconnectivity in Major Depression and Bipolar Disorder. Biol Psychiatry 79(4):293–302. https://doi.org/10.1016/j.biopsych.2015.03.004
Yucel K, McKinnon MC, Taylor VH, Macdonald K, Alda M, Young LT, MacQueen GM (2007) Bilateral hippocampal volume increases after long-term lithium treatment in patients with bipolar disorder: a longitudinal MRI study. Psychopharmacology 195(3):357–367. https://doi.org/10.1007/s00213-007-0906-9
Yucel K, Taylor VH, McKinnon MC, Macdonald K, Alda M, Young LT, MacQueen GM (2008) Bilateral hippocampal volume increase in patients with bipolar disorder and short-term lithium treatment. Neuropsychopharmacology 33(2):361–367. https://doi.org/10.1038/sj.npp.1301405
Zanni G, Michno W, Di Martino E, Tjarnlund-Wolf A, Pettersson J, Mason CE, Hellspong G, Blomgren K, Hanrieder J (2017) Lithium accumulates in neurogenic brain regions as revealed by high resolution ion imaging. Sci Rep 7:40726. https://doi.org/10.1038/srep40726
Zarate CA, Manji HK (2009) Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder. CNS Drugs 23(7):569–582. https://doi.org/10.2165/00023210-200923070-00003
Zarate CA Jr, Singh JB, Carlson PJ, Quiroz J, Jolkovsky L, Luckenbaugh DA, Manji HK (2007) Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord 9(6):561–570. https://doi.org/10.1111/j.1399-5618.2007.00530.x
Acknowledgements
I wish to thank Drs. Jose S. Aguilar-Marquez, Francisco Barrantes and Robert Schneider for critically reviewing the manuscript.
Author information
Authors and Affiliations
Contributions
E.L.M.O conceived the idea and wrote the paper.
Corresponding author
Ethics declarations
Competing interests
The author declares not to have competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ochoa, E.L.M. Lithium as a Neuroprotective Agent for Bipolar Disorder: An Overview. Cell Mol Neurobiol 42, 85–97 (2022). https://doi.org/10.1007/s10571-021-01129-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10571-021-01129-9